An Open-Label Extension to the Double-Blind SP515 (NCT00244387) Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease Who Are Not Well Controlled on L-Dopa.
Phase of Trial: Phase III
Latest Information Update: 29 Oct 2014
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational
- Sponsors Schwarz Pharma AG; UCB
- 10 May 2011 Updated study details, subject details, treatment tables and study centres.
- 07 Jan 2009 Planned number of patients changed from 360 to 395 as reported by ClinicalTrials.gov.
- 07 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.